The Managed Care Review Board^™ – Analyzing the Latest Advancements with Oral Anticoagulation Therapy

• Release date: October 10, 2014
• Expiration date: April 29, 2016
• Estimated Time to Complete Activity: 1.25 hours
• Compatible with (IE 6 and up, Firefox, Safari)

DISTINGUISHED FACULTY CONTRIBUTORS

Joseph E. Biskupiak, PhD, MBA Research Professor L.S. Skaggs Pharmacy Institute University of Utah Click here for biography

Chris Cannon, MD, FACC Professor, Department of Medicine Harvard Medical School Senior Physician Brigham and Women’s Hospital Click here for biography Jeffrey D. Dunn, PharmD, MBA Senior Vice President VRx Pharmacy Services, LLC Click here for biography John Fox, MD, MHA Senior Medical Director Associate Vice President, Medical Affairs Priority Health Click here for biography

TARGET AUDIENCE

• Medical Directors and Pharmacy Directors from health plans, HMOs, integrated health systems, employers, quality organizations, and other managed care organizations (MCOs)
• Managed care-affiliated care team members involved with patient evaluation, education, and follow-up for patients who require anticoagulation including: physicians, pharmacists, registered nurses, and case managers

STATEMENT OF NEED/PROGRAM OVERVIEW

An enhanced understanding of the pathophysiology of thromboembolic disorders has facilitated the development of novel therapies including factor Xa inhibitors and DTIs for preventing stroke and thromboembolism in at-risk patients. For managed care professionals and affiliated providers, enhanced competence is needed to assess and compare the three newly approved anticoagulant options. With the expected approval of a fourth such agent in 2014, the originators of the evidence-based treatment recommendations that guide clinical practice and therapeutic selection are challenged to define the roles of these new agents relative to warfarin. The uncertainty that providers experience as these are introduced and as treatment guidelines are revamped clearly justifies the need for robust educational efforts to inform managed care practitioners and decision makers of the key features of these new agents: mechanism of action, efficacy, safety, dosing, and monitoring.

By addressing practice gaps and reviewing the most current clinical and cost-effectiveness data available, this educational activity will help guide the audience to implement appropriate therapeutic and benefit-management strategies to reduce the risk of stroke and thromboembolism, two clinically-significant and costly diagnoses. Thought leaders from both clinical and managed care perspectives will recommend innovative strategies and practical methods to improve treatment success for patients who require anticoagulation to prevent stroke and systemic thromboembolism, while reducing the cost complexities associated with these pharmacologic advancements.

EDUCATIONAL OBJECTIVES
After completing this activity, the participant should be better able to:

• Evaluate recent advances in anticoagulant therapy, including clinical risks and benefits of evolving anticoagulants compared with standard treatments
• Deliver appropriate care and advice for patients who require anticoagulation to safely prevent stroke and systemic thromboembolism
• Recommend practice guidelines for patients who require anticoagulation to prevent stroke and systemic thromboembolism
• Employ comparative effectiveness analyses to enable evidence-based treatment decisions for patients who require anticoagulation to prevent stroke and systemic thromboembolism in a managed care setting
• Apply benefit design methodologies that MCOs can implement to improve the overall value (i.e., clinical outcomes, patient experience and financial burden) of anticoagulant therapies
• Provide accurate and appropriate counsel as part of the treatment team
• Provide appropriate care and counsel for patients and their families

ACCREDITATION

Physician Continuing Education

Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Annenberg Center for Health Sciences at Eisenhower and Impact Education, LLC. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
The Annenberg Center for Health Sciences at Eisenhower designates this monograph for a maximum of 1.25 AMA PRA Category 1 Credit(s)^™. Physicians should claim only the credit commensurate with the extent of their participation in this activity.

Pharmacy Continuing Education

Pharmacy Accreditation Statement

	The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation
This program has been developed according to the ACPE Criteria for Quality and is assigned ACPE Universal Activity # 0797-9999-14-129-H04-P. This program is designated for up to 1.1 contact hours (0.11 CEUs) of the continuing pharmacy education credit.

Type of Activity
Knowledge

Upon receipt of the completed activity evaluation form, transcript information will be available at www.mycpemonitor within 4 weeks.

Nursing Continuing Education

Accreditation Statement
Annenberg Center for Health Sciences is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Credit Designation
A maximum of 1.1 contact hours may be earned for successful completion of this activity.

A statement of credit will be issued only upon receipt of a completed activity evaluation form.

DISCLOSURE OF CONFLICTS OF INTEREST
The Annenberg Center for Health Sciences at Eisenhower assesses conflict of interest with its instructors, planners, managers and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for Health Sciences at Eisenhower for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center for Health Sciences at Eisenhower is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The planners and managers reported the following financial relationships or relationships to products of devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

METHOD OF PARTICIPATION AND REQUEST FOR CREDIT
There are no fees for participating and receiving CME/CE credit for this activity. During the period October 10, 2014 through April 29, 2016, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) successfully complete the post-test with a score of 75% or better; 4) and complete the evaluation form. Upon completion of the full CME/CE activity, a certificate will be made available immediately to download and print.

For Pharmacists: Upon receipt of the completed activity evaluation form, transcript information will be available at www.mycpemonitor within 4 weeks.

MEDIA
Monograph

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Annenberg Center for Health Sciences at Eisenhower, Postgraduate Institute for Medicine (PIM), Impact Education, LLC (IE), and commercial grantors do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the Annenberg Center for Health Sciences at Eisenhower, PIM, IE, and commercial grantors. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medication, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities

FEE INFORMATION
There is no fee for this educational activity.